(NASDAQ: ACLX) Arcellx's forecast annual revenue growth rate of 128.59% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.08%, and it is also forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Arcellx's revenue in 2025 is $35,898,000.On average, 18 Wall Street analysts forecast ACLX's revenue for 2026 to be $7,762,720,432, with the lowest ACLX revenue forecast at $1,699,992,407, and the highest ACLX revenue forecast at $17,447,473,096. On average, 15 Wall Street analysts forecast ACLX's revenue for 2027 to be $13,771,094,957, with the lowest ACLX revenue forecast at $6,913,302,457, and the highest ACLX revenue forecast at $19,749,979,819.
In 2028, ACLX is forecast to generate $26,209,950,967 in revenue, with the lowest revenue forecast at $14,151,569,449 and the highest revenue forecast at $38,006,973,108.